TISA-818治疗肺部感染所致ARDS的2期随机试验
主要终点安全性可接受,未出现非预期安全信号;非插管亚组 exploratory 分析中6mg每日两次在无呼吸支持天数等方面数值上优于安慰剂。
要点
- TISA-818总体耐受性良好,未发生药物相关严重不良事件或死亡。
- 第28天死亡率数值不平衡但未持续至第60天,可能反映小样本变异。
- 非插管亚组中6mg每日两次在多个疗效终点呈一致性数值改善。
核心结论
- TISA-818在肺部感染所致ARDS患者中总体耐受性良好,未出现非预期安全信号。
- 第28天死亡率数值不平衡但未持续,可能反映小样本变异,需谨慎解读。
- 非插管患者中6mg每日两次在多个疗效终点呈一致性数值改善,支持后续开展足够把握度的试验。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心2期试验,据研究者所知为中国首个采用2023全球ARDS定义的试验。
- 主要终点为安全性;关键次要终点包括第28天无呼吸支持天数、第14天存活且无呼吸支持比例、第14天临床改善率及28天内住院时长。
主要发现
- 治疗相关不良事件发生率在安慰剂组、6mg每日两次组和12mg每日一次组分别为5.3%、36.8%和21.1%,均为轻至中度。
- 第28天死亡率在安慰剂组、6mg每日两次组和12mg每日一次组分别为5.3%、10.5%和26.3%;第60天死亡率分别为26.3%、21.1%和31.6%。
- 预设非插管亚组(n=27,每组9例)探索性分析中,6mg每日两次组较安慰剂组无呼吸支持天数差异为6天(95%CI -3至15),所有次要终点呈一致性数值改善。
临床怎么用
- TISA-818在ARDS患者中安全性可接受,但疗效证据尚限于探索性分析,当前不应常规用于临床。
- 非插管ARDS患者可能从6mg每日两次方案中获益,但需在足够把握度的试验中进一步验证。
局限性
- 第28天死亡率数值不平衡但未持续,可能受小样本变异影响。
- 主要终点为安全性,疗效终点仅为次要或探索性,证据强度有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute respiratory distress syndrome (ARDS) remains associated with substantial mortality. The 2023 global definition includes non-intubated patients, creating an opportunity to evaluate therapies earlier in the disease course. RESEARCH QUESTION: Is TISA-818 safe and potentially efficacious in patients with ARDS, particularly those who are non-intubated? STUDY DESIGN AND METHODS: This randomized, double-blind, placebo-controlled, multicenter phase 2 trial was, to our knowledge, the first in China to use the 2023 global ARDS definition. Fifty-eight patients were randomized 1:1:1 to intravenous TISA-818 6 mg twice daily (BID), 12 mg once daily (QD), or matched placebo for 14 days. The primary endpoint was safety. Key secondary endpoints included respiratory support-free days (RSFDs) through day 28, proportion of patients alive and free from respiratory support at day 14, clinical improvement rate at day 14, and length of stay through 28 days. RESULTS: TISA-818 demonstrated an acceptable safety profile with comparable rates of treatment-emergent adverse events (AEs) and no unexpected safety signals. Treatment-related AEs were mild-to-moderate and occurred in 5.3%, 36.8%, and 21.1% of patients in the placebo, 6 mg BID, and 12 mg QD groups, respectively. Day-28 mortality was 5.3%, 10.5%, and 26.3%, whereas day-60 mortality was 26.3%, 21.1%, and 31.6% for placebo, 6 mg BID, and 12 mg QD, respectively. No drug-related serious AEs or deaths occurred. In the prespecified non-intubated subgroup (n=27, 9 per arm), exploratory analyses numerically favored 6 mg BID over placebo, with more RSFDs (difference, 6 days; 95% confidence interval, -3 to 15) and consistent numerical improvements across all secondary outcomes. INTERPRETATION: TISA-818 was generally well tolerated. Day-28 mortality was numerically imbalanced but not sustained, likely reflecting small-sample variability; cautious interpretation is warranted. Consistent improvements across all efficacy endpoints, particularly with 6 mg BID in non-intubated patients, support further investigation in adequately powered trials.
引用
- Huang L, Huang X, Jiao F, et al. TISA-818, an Anti-inflammatory Conjugate of Montelukast-Decapeptide, in Acute Respiratory Distress Syndrome Due to Pulmonary Infection: A Phase 2 Randomized Trial Using the 2023 Global Definition. Chest. 2026. PMID: 42829168. doi:10.1016/j.chest.2026.09.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。